<DOC>
	<DOCNO>NCT01003678</DOCNO>
	<brief_summary>This Phase I trial patient intermediate high risk myelodysplastic syndrome ( MDS ) . The study agent , clofarabine , produce Genzyme Pharmaceuticals .</brief_summary>
	<brief_title>Safety Tolerability Oral Clofarabine Intermediate High Risk Myelodysplastic Patients</brief_title>
	<detailed_description>The specific purpose study determine safety , maximum tolerate dose ( MTD ) recommend Phase II dose clofarabine patient MDS . - We start dose 1 mg daily . - We treat group 3 patient clofarabine dose level . - If severe side effect see dose level , next group 3 patient receive high dose . - Treatment group 3 patient continue high dose level severe side-effects note . - If 1 3 patient experience severe side effect , dose stop level . - If one three patient experience severe side effect , three patient treat , dose level experience severe side effect , dose escalation stop maximum tolerated dose determine . - 10 patient enrol maximum tolerated dose . - There 5 dose level test . - We plan test much drug patient 's blood different time , level certain protein blood .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<criteria>Provide sign write informed consent . Patients MDS must IPSS score fall intermediate high risk disease ( intermediate 1 transfusion dependent ) . Patients may receive two prior therapy MDS include one hypomethylating agent and/or biologic agent ( biologic agent include GMCSF equivalent , danazol equivalent , Sunitinib , Revlimid , ATG , vaccine ) . Age ≥ 18 Have adequate renal hepatic function indicate follow laboratory value : Serum creatinine ≤ 1 mg/dL ; serum creatinine &gt; l mg/dL , estimate glomerular filtration rate ( GFR ) must &gt; 50 mL/min/1.73 m2 calculate Modification Diet Renal Disease equation . Serum bilirubin ≤1.5 mg/dL x upper limit normal ( ULN ) Aspartate transaminase ( AST ) /alanine transaminase ( ALT ) ≤2.5 x ULN Alkaline phosphatase ≤2.5 x ULN Capable understand investigational nature , potential risk benefit study , able provide valid inform consent . Female patient childbearing potential must negative serum pregnancy test within 2 week prior enrollment . Male female patient must use effective contraceptive method study minimum 6 month study treatment . Have severe concurrent disease , history serious organ dysfunction disease involve heart , kidney , liver , organ system may place patient undue risk undergo treatment . Active CNS disease Patients systemic fungal , bacterial , viral , infection control ( define exhibit ongoing signs/symptoms related infection without improvement , despite appropriate antibiotic treatment ) . Pregnant lactating patient . Any significant concurrent disease , illness , psychiatric disorder would compromise patient safety compliance , interfere consent , study participation , follow , interpretation study result . Have prior treatment clofarabine Have diagnosis another malignancy , unless patient disease free least 3 year follow completion curative intent therapy , follow exception : Patients treat nonmelanoma skin cancer , situ carcinoma , cervical intraepithelial neoplasia , regardless diseasefree duration , eligible study definitive treatment condition complete . Patients organconfined prostate cancer evidence recurrent progressive disease base prostatespecific antigen ( PSA value also eligible study hormonal therapy initiate radical prostatectomy perform . Have prior positive test Human Immunodeficiency Virus ( HN ) . Have prior positive test Human Immunodeficiency Virus ( HN ) . Have currently active gastrointestinal disease , prior surgery may affect ability patient absorb oral clofarabine . Patients take proton pump inhibitor omeprazole ( Prilosec® ) , lansoprazole ( Prevacid® ) , esomeprazole ( Nexium® ) . Those stop take drug switch H2 blocker famotidine ( Pepcid® ) ranitidine ( Zantac® ) . Patients take alternative medicine ( herbal botanical ) permit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Myelodysplastic syndrome</keyword>
	<keyword>Clofarabine</keyword>
	<keyword>low-dose oral clofarabine</keyword>
	<keyword>intermediate risk Myelodysplastic syndrome</keyword>
	<keyword>high risk Myelodysplastic syndrome</keyword>
</DOC>